Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 1683  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission




 
 Table of Contents  
CASE REPORT
Year : 2021  |  Volume : 13  |  Issue : 6  |  Page : 1728-1732  

Olfactory neuroblastoma managed with endoscopic sinus surgery


1 Department of Otorhinolaryngology-Head and Neck Surgery, Alhada Armed Forces Hospital, Taif, Saudi Arabia
2 General Practitioner, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia
3 Medical Intern, College of Medicine, Taif University, Taif, Saudi Arabia

Date of Submission05-Feb-2021
Date of Decision25-Mar-2021
Date of Acceptance09-Apr-2021
Date of Web Publication10-Nov-2021

Correspondence Address:
Althumali Abdulaziz Hameed
King Abdulaziz Specilaist Hospital, Taif
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpbs.jpbs_62_21

Rights and Permissions
   Abstract 


Olfactory neuroblastoma (ONB) or esthesioneuroblastoma is a rare malignancy of the nose and paranasal sinuses that originates from the upper nasal vault. We report a rare case of ONB in a 27-year-old female patient with a 2-year history of nasal obstruction, sneezing, nasal discharge, and left eye protrusion. The patient was successfully treated with endoscopic sinus surgery and adjuvant radiotherapy (RT) with 5-year follow-up duration. Studying ONB cases is of great importance due to its rare occurrence, and the lack of literature regarding its management often creates a dilemma leading to nonstandardized treatment methods. Prolonged surveillance is essential due to its late recurrence and endoscopic resection followed by adjuvant RT, which may be a feasible and effective treatment. There is no single case of ONB published yet in Saudi Arabia, and to our knowledge, this is the first case report.

Keywords: Malignancy, neuroblastoma, neuroectoderm, sinus


How to cite this article:
Al-Osaimi SM, Hameed AA, Alsufyani AA, Altwairqi RG, Alotaibi AF. Olfactory neuroblastoma managed with endoscopic sinus surgery. J Pharm Bioall Sci 2021;13, Suppl S2:1728-32

How to cite this URL:
Al-Osaimi SM, Hameed AA, Alsufyani AA, Altwairqi RG, Alotaibi AF. Olfactory neuroblastoma managed with endoscopic sinus surgery. J Pharm Bioall Sci [serial online] 2021 [cited 2022 Jun 28];13, Suppl S2:1728-32. Available from: https://www.jpbsonline.org/text.asp?2021/13/6/1728/330142




   Introduction Top


Olfactory neuroblastoma (ONB) is a rare neuroectodermal malignancy that occurs in the upper vault of the sinonasal cavity.[1] Epidemiological data show that the incidence of ONB is 0.4 per million population with no gender predilection and show a bimodal age distribution with peak rates at the 2nd and 6th decades of life.[2],[3] The most common anatomic origin of ONB is in the upper vault of the nasal cavity near the cribriform plate, while other sites of origin proposed are ectodermal olfactory placode, Jacobson's organ (vomeronasal organ), sphenopalatine ganglion, the ganglion of loci, autonomic ganglia in the nasal mucosa, and the olfactory epithelium itself.[4]

ONB usually presents as unilateral nasal obstruction followed by epistaxis and less commonly headache, pain, rhinorrhea, excessive lacrimation, anosmia, and visual disturbances, such as diplopia and proptosis.[5],[6],[7] The biological activity of ONB varies from indolent up to highly aggressive, and furthermore, it is considered ectopic if it originates from the lower nasal cavity within one of the paranasal sinuses and exists as an intracranial mass with cribriform plate involvement, or in extremely rare cases, intracranially with no intranasal component.[8] Reported ectopic ONB sites of origin include the anterior ethmoids, sphenoid sinus, maxillary sinus, pituitary gland, nasopharynx, sellar region, nasal cavity inferior meatus, and noise floor.[9] The management of ONB usually follows a multidisciplinary that includes surgery, chemotherapy, and radiotherapy (RT). Cases treated with combination of surgery and RT have shown superior survival rates and life expectancy.[10],[11] This present study reports the case of a Saudi female patient with a 2-year history of nasal obstruction, sneezing, nasal discharge, and left eye protrusion treated by endoscopic surgical excision RT with a 5-year follow-up duration.


   Case Report Top


We report a 27-year-old female with previously diagnosed hypothyroidism with a 2-year history of bilateral nasal obstruction that was more profound on the left side, sneezing, and nasal discharge followed by left eye protrusion with no visual disturbances, no history of trauma, photophobia, ocular pain, colored halos, floaters, and redness. The patient's complaint worsened when she was a 16-week primigravida with progressively growing left nasal polyp. Drug intake history consisted of levothyroxine. Family history revealed breast cancer in two of her third-degree relatives; otherwise, her medical history was unremarkable. There was no evidence of neck mass on physical examination, and on ocular examination, there was mild proptosis in the left eye. Visual acuity and fundal examination were within normal limits, and there was no pain or restriction with ocular movement. Endoscopic examination showed a polypoid mass on the left side and right nasal septal deviation. A computed tomography (CT) scan of the head without contrast showed a lobulated soft-tissue mass occupying the left side of the paranasal sinuses and nasal cavity. A computed tomography (CT) scan of the head without contrast showed a lobulated soft-tissue mass occupying the left side of the paranasal sinuses and nasal cavity with bony erosions in the left maxillary sinus. Endoscopic sinus surgery was done, and an excisional biopsy from left nasal polyp and left maxillary polyp was obtained. Gross examination showed multiple fragments of whitish-to-dark brown, soft bony tissue of the left nasal polyp, and pale tan tissue fragments of the left maxillary polyp. Hematoxylin-eosin (H and E) staining of specimens showed hypercellular neoplastic proliferation with lobular architecture with infiltrative patterns of small nests of cells in neurofibrillary material, pseudorosettes (Homer Wright rosettes) were focally present, showed scattered mitosis, individual necrotic cells, and scattered patchy necrosis. Neoplastic cells demonstrated indistinct cell borders, moderately pleomorphic nuclei with stippled chromatin. Histological diagnosis was ONB Grade 2–3 based on the Hyams grading system. Immunohistochemical staining for synaptophysin, neuron-specific enolase (NSE), chromogranin, Ki-67, and S-100 protein were positive, while cytokeratin was negative. Postoperative histopathology confirmed a positive result for ONB.

An magnetic resonance imaging (MRI) scan was carried out 2 weeks after the endoscopic operation and showed irregular homogeneously enhanced soft tissue in the form of intermediate signal intensity on the T2 image and low signal intensity on the T1 images seen at the most upper part of the left anterior ethmoidal air cells extending superiorly to the lateral aspect of the crista galli with no cortical involvement. The lesion minimally crossed the midline and encroached on the left orbit to reach the extraconal space. The lesion compressed the medial rectus muscle with no muscular invasion and anteriorly got into the left maxillary sinus with postoperative changes in the left maxillary sinus after left maxillary polyp removal. This presentation corresponded to Kadish Stage B. After a multidisciplinary tumor board discussion, a bimodality treatment approach consisting of endoscopic resection followed by adjuvant RT was considered. The patient was treated with a wide tumor excision by endoscopic sinus surgery, and biopsies were taken from the shaved ruminants from left anterior and posterior ethmoid air cells and frontal recess. CT pan scans were done in which negative results for distant metastasis were found. After that, the patient subsequently received adjuvant external beam radiation for 6 weeks with a total dose of 60 Gy/30 fractions delivered with a step and shoot (S and S) intensity-modulated radiotherapy (IMRT) technique. After proper immobilization, a planning CT simulation with a 3-mm slice thickness was performed. RT was well tolerated without side effects. After a stable period of a 17-month follow-up using nasal endoscopy and imaging, endoscopic findings were suspicious. A re-biopsy was done, which showed a negative left ethmoid sinus involvement and a positive left frontal recess involvement. The patient underwent a second surgery using endoscopic sinus surgery. After that, re-biopsy from all involved sinuses was done and yielded negative results. During the next 38-month follow-up period, the patient remained clinically and radiologically free of disease recurrence.


   Discussion Top


ONB clinical presentation depends on the mass effect or local invasion of the involved part, including the paranasal sinuses, orbits, metastatic spread to cervical lymph nodes, intracranial space, or rarely, distant metastasis, such as the bones.[3],[12],[13] Symptomatic presentation of ONB most commonly involves unilateral nasal obstruction followed by epistaxis, and less commonly headache, pain, rhinorrhea, excessive lacrimation, anosmia, and visual disturbances such as diplopia and proptosis.[14],[15] Physical findings include nasal mass, proptosis, extraocular paralysis, neck and nasopharyngeal masses, hyponatremia, Cushingoid appearance, and behavioral changes due to frontal lobe involvement.[16],[17] It is reported that the biological activity of ONB varies from indolent growth rate with patient survival >20 years up to highly aggressive neoplasm with metastatic spread and patient survival for a few months.[14]

Imaging modalities such as CT and MRI are considered as gold standard imaging modality to diagnose ONB.[9],[18] ONB appears on contrast-enhanced CT as homogeneous soft-tissue mass with moderate and uniform enhancement.[19] CT with no contrast is used to assess the presence of speckled calcification and bone erosion of the cribriform plate, lamina papyracea, and fovea ethmoidalis. MRI uses pre- and post-contrast image after gadolinium injection, where it appears as hypointense areas compared to gray matter on T1-weighted image and hyperintense areas on the T2-weighted image.[9],[19] The classic and characteristic feature of ONB that appears in imaging studies is its “dumbbell-shaped” mass extending across the cribriform plate.[20],[21]

Kadish et al. established a clinical staging system for ONB in 1976 that has been used until today. This stage includes three classifications: (a) Stage A: tumor limited to the nasal cavity, (b) Stage B: nasal cavity and one or more paranasal sinus, and (c) Stage C: beyond nasal cavity and paranasal sinuses.[22] Morita et al. modified the Kadish system by adding Stage D, which includes cervical lymph nodes or distant metastases.[23] [Table 1] demonstrates the different clinical staging systems.
Table 1: Kadish, Morita, and Dulguerov tumor node metastasis staging systems

Click here to view


On histopathological evaluation, H and E staining in low-power magnification showed a Grade 2–3 ONB arranged in lobules and separated by the neurofibrillary matrix [Figure 1]a. Simultaneously, H and E staining in high-power magnification demonstrated Grade 2–3 ONB with sheets of anaplastic tumor cells [Figure 1]b.
Figure 1: (a) H and E stain low-power magnification Grade 2–3 olfactory neuroblastoma arranged in lobules and separated by neurofibrillary matrix. (b) H and E stain high-power magnification Grade 2–3 olfactory neuroblastoma with sheets of anaplastic tumor. (c) Tumor cell demonstrating diffuse and strong cytoplasmic positivity for neuron-specific enolase immunohistochemical stain

Click here to view


Hyams' grading system was created using histopathological patterns to grade ONB from Grade 1, which is the most well differentiated up to Grade 4 and is the most anaplastic form based on the presence of neural stroma, the degree of differentiation, mitotic figures, and necrosis.[24] [Table 2] illustrates Hyams' histopathological grading system. Immunohistochemical staining plays a vital role in differentiating ONB from other sinonasal small round blue cell tumors, as described by Rooper and Bishop.[15] The most expressed marker is NSE, and ONB is classically reactive for synaptophysin, chromogranin, and S-100 protein limited to the sustentacular cells.[15],[25] [Figure 1]c is demonstrating diffuse and strong cytoplasmic positivity for NSE immunohistochemical stain.
Table 2: Hyams' histopathological grading system

Click here to view


It is difficult to determine a standard treatment strategy due to its anatomic location variation, rarity, limited information in the literature, and lack of randomized control trials.[26],[27] Bailey and Barton reported in their case series of ONB that combined surgery and radiation therapy showed better cure rates, survival rates, and life expectancy than surgery or RT alone.[28] Endoscopic techniques are more commonly used for Kadish A and B stages since they are less invasive lesions, while open surgeries are used with higher stages.[29] In extensive tumor cases, a lateral rhinotomy approach, resection of the nose's lateral wall, and in some cases, complete resection of the cribriform plate could be performed.[30] Prolonged follow-up with imaging modalities is recommended due to late tumor recurrence rates.[28]


   Conclusion Top


To our knowledge, this is the first published adult Saudi case of ONB. ONB should be considered a differential diagnosis for nasal and paranasal sinus masses to prevent delay in management. Minimally invasive endoscopic sinus surgery with adjuvant IMRT is a valid choice in this setting and has favorable outcomes. Further studies are needed to assess cases of ONB to achieve optimal management strategies and standard follow-up guidelines.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Acknowledgments

All the authors would like to thank and express their deep gratitude toward the faculty at the departments of pathology and radiation oncology for their valuable assistance.

Financial support and sponsorship

Nil.

Conflicts of interest

Written consent was taken from the patient. All the authors declare the there is no conflict of interests, including specific financial interests, relationships, and affiliations.



 
   References Top

1.
Berger L, Luc R. L'esthesioneuroepitheliome olfactif. Bull Assoc Fr Etude Cancer 1924;13:410-21.  Back to cited text no. 1
    
2.
Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: A general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997;17:2683-706.  Back to cited text no. 2
    
3.
Thompson LD. Olfactory neuroblastoma. Head Neck Pathol 2009;3:252-9.  Back to cited text no. 3
    
4.
Dublin AB, Bobinski M. Imaging characteristics of olfactory neuroblastoma (esthesioneuroblastoma). J Neurol Surg B Skull Base 2016;77:1-5.  Back to cited text no. 4
    
5.
Peng X, Liu Y, Peng X, Wang Z, Zhang Z, Qiu Y, et al. Clinical features and the molecular biomarkers of olfactory neuroblastoma. Pathol Res Pract 2018;214:1123-9.  Back to cited text no. 5
    
6.
Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, et al. Esthesioneuroblastoma: The princess Margaret hospital experience. Head Neck 2008;30:1607-14.  Back to cited text no. 6
    
7.
Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: Past, present, and future? Laryngoscope 2003;113:502-7.  Back to cited text no. 7
    
8.
Czapiewski P, Kunc M, Haybaeck J. Genetic and molecular alterations in olfactory neuroblastoma: Implications for pathogenesis, prognosis and treatment. Oncotarget 2016;7:52584-96.  Back to cited text no. 8
    
9.
Caldwell NJ, Sato TS. Ectopic primary olfactory neuroblastoma of the nasopharynx: A case report and review of the literature. Radiol Case Rep 2019;14:997-1002.  Back to cited text no. 9
    
10.
Kumar R. Esthesioneuroblastoma: Multimodal management and review of literature. World J Clin Cases 2015;3:774-8.  Back to cited text no. 10
    
11.
Petruzzelli GJ, Howell JB, Pederson A, Origitano TC, Byrne RW, Munoz L, et al. Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence. Am J Otolaryngol 2015;36:547-53.  Back to cited text no. 11
    
12.
Tajudeen BA, Arshi A, Suh JD, Palma-Diaz MF, Bergsneider M, Abemayor E, et al. Esthesioneuroblastoma: An update on the UCLA experience, 2002-2013. J Neurol Surg B Skull Base 2015;76:43-9.  Back to cited text no. 12
    
13.
Hwang SK, Paek SH, Kim DG, Jeon YK, Chi JG, Jung HW. Olfactory neuroblastomas: Survival rate and prognostic factor. J Neurooncol 2002;59:217-26.  Back to cited text no. 13
    
14.
Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: A meta-analysis and review. Lancet Oncol 2001;2:683-90.  Back to cited text no. 14
    
15.
Rooper LM, Bishop JA. Sinonasal small round blue cell tumors: An immunohistochemical approach. Surg Pathol Clin 2017;10:103-23.  Back to cited text no. 15
    
16.
Ward PD, Heth JA, Thompson BG, Marentette LJ. Esthesioneuroblastoma: Results and outcomes of a single institution's experience. Skull Base 2009;19:133-40.  Back to cited text no. 16
    
17.
Koka VN, Julieron M, Bourhis J, Janot F, Le Ridant AM, Marandas P, et al. Aesthesioneuroblastoma. J Laryngol Otol 1998;112:628-33.  Back to cited text no. 17
    
18.
Cante D, Piva C, Sciacero P, Franco P, Petrucci E, Casanova Borca V, et al. Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature. BJR Case Rep 2018;4:20170077.  Back to cited text no. 18
    
19.
Pickuth D, Heywang-Köbrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: An analysis of 22 cases. Clin Otolaryngol Allied Sci 1999;24:457-61.  Back to cited text no. 19
    
20.
Gandhoke CS, Dewan A, Gupta D, Syal SK, Jagetia A, Saran RK, et al. A rare case report of mixed olfactory neuroblastoma: Carcinoma with review of literature. Surg Neurol Int 2017;8:83.  Back to cited text no. 20
  [Full text]  
21.
Kunimatsu A, Kunimatsu N. Skull base tumors and tumor-like lesions: A pictorial review. Pol J Radiol 2017;82:398-409.  Back to cited text no. 21
    
22.
Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976;37:1571-6.  Back to cited text no. 22
    
23.
Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: Prognosis and management. Neurosurgery 1993;32:706-14.  Back to cited text no. 23
    
24.
Hyams VJ, Batsakis JG, Michaels L. Tumors of the upper respiratory tract and ear. In: Armed Forces Institute of Pathology Fascicles. 2nd series. Washington: American Registry of Pathology Press; 1988.  Back to cited text no. 24
    
25.
Barnes L, Eveson JW, Sidransky D, Reichart P, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.  Back to cited text no. 25
    
26.
Abdelmeguid AS. Olfactory Neuroblastoma. Curr Oncol Rep. 2018;20:7.  Back to cited text no. 26
    
27.
Fiani B, Quadri SA, Cathel A, Farooqui M, Ramachandran A, Siddiqi I, et al. Esthesioneuroblastoma: A comprehensive review of diagnosis, management, and current treatment options. World Neurosurg 2019;126:194-211.  Back to cited text no. 27
    
28.
Bailey BJ, Barton S. Olfactory neuroblastoma. Management and prognosis. Arch Otolaryngol 1975;101:1-5.  Back to cited text no. 28
    
29.
Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: A 16-year meta-analysis of 361 patients. Laryngoscope 2009;119:1412-6.  Back to cited text no. 29
    
30.
Faragalla H, Weinreb I. Olfactory neuroblastoma: A review and update. Adv Anat Pathol 2009;16:322-31.  Back to cited text no. 30
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed264    
    Printed6    
    Emailed0    
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal